- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00284791
Lamotrigine in Treatment Resistant Depression in Adolescents
Lamotrigine Use in Treatment Refractory Depression in Adolescents
The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).
Our Primary Aim is to determine the efficacy and safety of Lamotrigine-augmentation of fluoxetine for treatment-resistant depression in adolescents.
Our Secondary Aims are to characterize the factors associated with treatment-resistance for adolescents with major depression. Also to assess the relationships in the families of adolescents with major depression as they enter treatment, and to track the differences in family relationships for adolescents who respond or do not respond. We postulate that tense, frustrated, irritable, and over-involved relationships constitute a risk factor for attenuated improvement or relapse.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mood disorders in youth, which include Major Depressive Disorder (MDD) and Bipolar Disorder (BPD), are highly prevalent, and are associated with significant mortality and morbidity. Many youths with major depression fail first-line treatments with psychotherapy and psychotropic medications. Lamotrigine (Lamictal®) recently gained approval by the FDA for maintenance treatment of bipolar disorder in adults. A few pilot studies have also shown promising results for lamotrigine (LTG) in treatment refractory mood disorders in both youth and adults, especially for depressive symptoms (Carandang et al., 2003; Frye et al., 2000).
For this proposed study, the modified design begins with adolescents with major depressive disorder who have not responded to a trial of a selective serotonin reuptake inhibitor antidepressant (SSRI), fluoxetine, of adequate dose and duration, and randomizes them either to a second SSRI or to fluoxetine augmented by lamotrigine. Non-responders to 8 weeks of fluoxetine, on at least 40 mg/day, who have not had to discontinue fluoxetine because of adverse effects, would be randomized to: (A) continue fluoxetine with lamotrigine augmentation, for 8 weeks, as in the active arm of the original Stage 2, or (B) discontinue fluoxetine and begin a second SSRI, for 8 weeks. We will use sertraline as the second SSRI, because of the data supporting efficacy from the randomized placebo-controlled trial by Wagner, et.al. (JAMA, '03). Citalopram is also a possibility (Wagner et.al, Am J. Psychiatry '04), but it has been in use for a shorter period of time than sertraline.
To maintain the blind, the B group will receive placebo augmentation.
The assessments and outcome measures would be the same as in the original study. We will consult with primary care offices to coach them through doing the initial, Stage 1, fluoxetine trial in their offices, and we will monitor the progress of adolescents started on fluoxetine in our clinic. Consent will be discussed only with those who are not responding, and treatment in the study will involve only the post-randomization treatment.
Background
Mood disorders in youth are common and debilitating. Early-onset of mood disorders often indicates a severe illness, with high likelihood of recurrence into adulthood. For prepubertal children, point prevalence of MDD is 2%, and 6% in adolescents, while the lifetime prevalence for MDD in adolescents is 20% (Birmaher et al., 2002). The duration of a Major Depressive Episode in youth ranges from 3 to 9 months, with 10% lasting more than 2 years, 60-70% recurring in adulthood, and 20-40% developing Bipolar Disorder within 5 years (Weller and Weller, 2000). The prevalence of prepubertal bipolar disorder is estimated at 0.5%. Prevalence of bipolar disorder in adolescents is 1% (Lewinshon et al., 1995). Suicide is the third leading cause of death in the 15 - 24 year old age group (10.1 per 100,000) and the fifth leading cause in the 5 - 14 year old group (0.7 per 100,00), and is highly correlated with MDD and BPD (Pfeffer, 2002). In addition, mood disorders in youth can impair functioning, often characterized by poor school performance, impaired relationships, delinquent behavior, and substance abuse.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maine
-
Portland, Maine, United States, 04102
- Maine Medical Center Outpatient Psychiatry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescents (13-17) diagnosed with a major depressive episode (MDE) (DSM-IV criteria) from either major depressive disorder (MDD) or bipolar disorder (BPD). BPD can present as a major depressive episode, with previous or subsequent cycling into a hypomanic, manic, or mixed episode. By definition, major depressive disorder MDD requires the presence of a major depressive episode, without cycling into a hypomanic, manic, or mixed episode.
- CDRS (Children's Depression Rating Scale) > 40.
CGAS (Children's Global Assessment Scale) < 60.
- Exclusion Criteria:
Adolescents who meet the following criteria will be excluded from the study:
- Prior medically serious suicide attempt, within 3 months of enrollment into study or a score of 3 on suicide questions within KSADS at initial visit or the side effect checklist on follow up visits regarding current state.
- Known or suspected mental retardation. For patients with known mental retardation, full scale IQ below 70 should be documented.
- Current significant physical illnesses (e.g. diabetes mellitus, asthma, cystic fibrosis, congenital heart defects, genetic disorders). Patients with seizure disorders taking anticonvulsants will be excluded (no concomitant anticonvulsants).
- Current drug or alcohol abuse. No active abuse will be permitted within two weeks of beginning the study trial (confirmed by urine testing in all cases of suspected abuse).
- Females who are sexually active and are unwilling or considered unable to use appropriate contraception.
- Use of benzodiazepines and other anxiolytics, antipsychotic medications, other antidepressants, stimulant medication, other mood stabilizers (e.g., lithium, valproate), and other sedative-hypnotics will not be permitted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Douglas R Robbins, MD, Maine Medical Center Psychiatry Department
- Study Director: William McFarlane, MD, Maine Medical Center, Center for Psychiatric Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Anticonvulsants
- Antidepressive Agents, Second-Generation
- Sodium Channel Blockers
- Cytochrome P-450 CYP2D6 Inhibitors
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Sertraline
- Lamotrigine
- Fluoxetine
Other Study ID Numbers
- MMC-2571
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adolescent Depression
-
University of North Carolina, Chapel HillFoundation of Hope, North CarolinaRecruiting
-
Creighton UniversityThrasher Research FundCompletedAdolescent DepressionUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)RecruitingAdolescent Depression | Adolescent SuicideUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)CompletedAdolescent Behavior | Resilience, Psychological | Depression MildUnited States
-
University of British ColumbiaCompletedEducation of Therapists Treating Adolescent DepressionCanada
-
University of North Carolina, Chapel HillUniversity of Colorado, Denver; Doris Duke Charitable Foundation; University... and other collaboratorsNot yet recruitingDepression | Anxiety | Adolescent Behavior | Mental Health Issue | Psychosocial Functioning | Adolescent - Emotional ProblemIndia
-
Vanderbilt University Medical CenterThe Klingenstein Third Generation FoundationCompletedDepression | Adolescent DepressionUnited States
-
Icahn School of Medicine at Mount SinaiNational Center for Complementary and Integrative Health (NCCIH); National...Completed
-
Shalvata Mental Health CenterUnknownAdolescent DepressionIsrael
-
Washington University School of MedicineWashington University Institute of Clinical and Translational SciencesCompletedAnxiety Disorders | Adolescent DepressionUnited States
Clinical Trials on Lamotrigine (drug)
-
GlaxoSmithKlineCompleted
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
University of Texas Southwestern Medical CenterCompletedMemory Impairment Due to Corticosteroid Use | Hypomania Due to Corticosteroid Use | Hippocampal Atrophy Due to CorticosteroidUnited States
-
University of Maryland, BaltimoreCompleted
-
GlaxoSmithKlineCompletedEpilepsy, PartialUnited States, Korea, Republic of, Ukraine, Chile, Costa Rica, Russian Federation, Puerto Rico, Argentina
-
University of ChicagoCompletedDermatillomania | Pathologic Skin Picking | Neurotic Excoriation | Psychogenic ExcoriationUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
GlaxoSmithKlineCompleted